» Articles » PMID: 32823851

Toxicological Profile of the Pain-Relieving Antioxidant Compound Thioctic Acid in Its Racemic and Enantiomeric Forms

Overview
Date 2020 Aug 23
PMID 32823851
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Thioctic acid is a multipotent antioxidant compound existing as dextrorotatory (+), eutomer and naturally occurring and levorotatory (-). It has been proven to help fight many pathologies and is sold as racemate. In agreement with studies claiming a greater biopotency of the eutomer compared to the levorotatory compound, we recently preclinically and clinically showed that (+) thioctic acid is a pain-reliever as effective as double-dosed racemate. We investigated acute and subchronical toxicity of (+/-) thioctic acid, (-) thioctic acid, (+) thioctic acid and (+) salt thioctic acid on Sprague-Dawley rats. For acute toxicity, compounds were administered intraperitoneally (i.p.) with a single-injection at 125, 240, 360, 480 µmol/kg, then rodents were tested for motorial coordination and minimum lethal dose (LDmin). A subtoxic dose (360 µmol/kg) was administered i.p. for 15 days and we finally evaluated motorial impairment, glycemia, organ toxicity, and apoptosis state. Acutely administered, the highest doses of all thioctic acid compounds negatively affected motorial ability and (-) thioctic acid LDmin resulted higher than the others. Subchronic administrations caused overall body weight loss, motorial impairment, mass loss in some organs. (+/-) and (-) thioctic acid injections enhanced caspase-3 activity in some organs, (-) enantiomer-treated animals displayed more marked organ toxicity signs. Together with our previous study on the biologic role of enantiomers, these data suggest a therapeutic use of (+) enantiomer-based formulations, thus lowering dose and toxicity without affecting the positive effects brought by the drug.

Citing Articles

Nanotechnological Approaches to Enhance the Potential of α-Lipoic Acid for Application in the Clinic.

Bellini C, Mancin F, Papini E, Tavano R Antioxidants (Basel). 2024; 13(6).

PMID: 38929145 PMC: 11201002. DOI: 10.3390/antiox13060706.


Evaluation of the protective roles of alpha-lipoic acid supplementation on nanomaterial-induced toxicity: A meta-analysis of and studies.

Luo X, Xie D, Wu T, Xu W, Meng Q, Cao K Front Nutr. 2022; 9:991524.

PMID: 36147302 PMC: 9486203. DOI: 10.3389/fnut.2022.991524.


Antioxidant Properties of Alpha-Lipoic (Thioctic) Acid Treatment on Renal and Heart Parenchyma in a Rat Model of Hypertension.

Martinelli I, Tomassoni D, Roy P, Di Cesare Mannelli L, Amenta F, Tayebati S Antioxidants (Basel). 2021; 10(7).

PMID: 34201726 PMC: 8300705. DOI: 10.3390/antiox10071006.


Comparative Assessment of the Activity of Racemic and Dextrorotatory Forms of Thioctic (Alpha-Lipoic) Acid in Low Back Pain: Preclinical Results and Clinical Evidences From an Open Randomized Trial.

Pacini A, Tomassoni D, Trallori E, Micheli L, Amenta F, Ghelardini C Front Pharmacol. 2021; 12:607572.

PMID: 33732153 PMC: 7959756. DOI: 10.3389/fphar.2021.607572.

References
1.
Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B . Lipoic acid - biological activity and therapeutic potential. Pharmacol Rep. 2011; 63(4):849-58. DOI: 10.1016/s1734-1140(11)70600-4. View

2.
M El-Sayed E, Mansour A, El-Sawy W . Alpha lipoic acid prevents doxorubicin-induced nephrotoxicity by mitigation of oxidative stress, inflammation, and apoptosis in rats. J Biochem Mol Toxicol. 2017; 31(9). DOI: 10.1002/jbt.21940. View

3.
Ziegler D, Hanefeld M, Ruhnau K, Hasche H, Lobisch M, Schutte K . Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999; 22(8):1296-301. DOI: 10.2337/diacare.22.8.1296. View

4.
Vasdev S, Ford C, Parai S, Longerich L, Gadag V . Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000; 18(5):567-73. DOI: 10.1097/00004872-200018050-00009. View

5.
Ziegler D, Hanefeld M, Ruhnau K, MEISSNER H, Lobisch M, Schutte K . Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995; 38(12):1425-33. DOI: 10.1007/BF00400603. View